Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-01-21

Clinical Trial Update: A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating long-term safety of Certolizumab Pegol in Crohn's disease completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Certolizumab pegol (certolizumab pegol)

Snippet

Sponsor: UCB BIOSCIENCES GmbH | Conditions: Crohn Disease | Phase 3 | Status: COMPLETED | Results posted: 2016-01-21